stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.89
2.43
+5.01%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Shares outstanding
MBX Biosciences, Inc.'s shares outstanding at the end of fiscal 2025 was $36.5M, up 243.0% from $10.6M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $47.7M. MBX Biosciences, Inc. ranks 300th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $36.5M | 243.00% |
| FY2024 | $10.6M | 944.46% |
| FY2023 | $1.0M | 52.77% |
| FY2022 | $667.0K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $47.7M | 2.40% |
| Mar 2026 | $46.6M | 27.58% |
| Dec 2025 | $36.5M | 6.75% |
| Sep 2025 | $34.2M | 2.25% |
| 7 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| RCUS Arcus Biosciences, Inc. compare | $127.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $111.7M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| XNCR Xencor, Inc. compare | $75.9M |
| PHVS Pharvaris N.V. compare | $68.1M |
| MBX MBX Biosciences, Inc. | $47.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item